<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989999</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.106</org_study_id>
    <nct_id>NCT03989999</nct_id>
  </id_info>
  <brief_title>Transcranial Ultrasonography for the Management of Patients With Mild TBI</brief_title>
  <acronym>TRUST</acronym>
  <official_title>Transcranial Ultrasonography for the Management of Patients With Mild Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that patients with mild TBI and normal TCD can be safely
      discharged home immediately after the ED. The targeted population is the category of patients
      eligible for early discharge: 1) patients with mild lesions on the initial CT scan and a GCS
      15 after CT scan completion and, 2) patients with no lesion on the initial cerebral CT scan
      with at least one of the following risk factors: GCS 14 after CT scan completion, persisting
      post-traumatic nausea/vomiting/headaches, concomitant alcoholic intoxication or patients
      treated with aspirin. The study will not include mild TBI patients who are not eligible for
      early discharge: patients with no possibility of home supervision, those with a GCS lower
      than 14 after the CT scan or those treated with anticoagulant/antiplatelet drugs other than
      aspirin. The investigators expect the TCD-based strategy to be non-inferior compared to the
      standard strategy according to French recommendations in terms of the 3-months neurological
      outcome. From a public health standpoint, the use of TCD as a triage tool may change current
      guidelines regarding mild TBI management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with mild traumatic brain injury (TBI) represent the vast majority of TBI patients
      admitted in the emergency department (ED). According to French recommendations, mild TBI
      patients with brain lesions on initial CT scan are directed to a standard ward, where
      neurologic monitoring consists of repeated CT scanning and clinical exams. Patients with no
      lesion on initial cerebral CT scan are also hospitalized 1) when their GCS after CT scan is
      lower than 15, 2) in case of persisting nausea, vomiting or headache, 3) in case of
      concomitant alcoholic intoxication and, 4) in case of on-going treatment with aspirin. This
      strategy induces significant hospital stay with potential morbidity, whereas neurologic
      worsening rarely occurs.

      In this context, the implementation of a triage tool in the ED would be useful to screen
      patients at risk of early neurologic worsening. Hence, low risk patients may be discharged at
      home immediately after the ED. Transcranial Doppler (TCD) is a non-invasive technique that
      measures cerebral blood flow velocities in intracranial cerebral arteries. These velocities
      and a derivated parameter (pulsatility index, PI), estimate cerebral blood flow (CBF) and
      have become a standard of care to optimize CBF in after severe TBI. Only few studies report
      the use of TCD after mild TBI. In a single-center cohort of patients with mild-to-moderate
      TBI, TCD parameters measured at hospital admission accurately predicted early neurologic
      worsening. These encouraging results indicate that TCD, in combination with CT scan findings,
      could play a role in the management of patients with mild TBI.

      The aim of this project is to determine whether a TCD-based strategy is non-inferior to the
      standard management in terms of the overall neurological outcome at 3 months after mild TBI
      with no/minor lesions detected on a cerebral CT scan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicenter, open, non-inferiority, randomized, controlled, study with blinded evaluation.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The evaluation at 3 months after TBI will be centralized by the coordinating centre and blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of a TCD-based strategy after a mild TBI to the standard management in terms of the overall neurological outcome</measure>
    <time_frame>3 months after TBI</time_frame>
    <description>GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on the overall neurological outcome</measure>
    <time_frame>1 month after TBI</time_frame>
    <description>GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on the quality of life</measure>
    <time_frame>1 months after TBI</time_frame>
    <description>Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on the quality of life</measure>
    <time_frame>3 months after TBI</time_frame>
    <description>Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome</measure>
    <time_frame>1 month after TBI</time_frame>
    <description>Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI (&quot;Rivermead positive&quot; patients are patients with at least 3 symptoms rated ≥ 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome</measure>
    <time_frame>3 months after TBI</time_frame>
    <description>Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI (&quot;Rivermead positive&quot; patients are patients with at least 3 symptoms rated ≥ 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on Morbidity after TBI</measure>
    <time_frame>1 months after TBI</time_frame>
    <description>Number of cerebral CT scans within the hospital stay, • Thromboembolic events or diagnosed nosocomial infections stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on mortality after TBI</measure>
    <time_frame>3 months after TBI</time_frame>
    <description>Mortality within the first 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a TCD-based strategy after a mild TBI on patient safety</measure>
    <time_frame>3 months after TBI</time_frame>
    <description>Number of patients with neurologic worsening within the first week after TBI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">984</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>TCD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial Doppler within 8 hours of traumatic injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Mild TBI management with SFMU recommandations</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial Doppler (TCD)</intervention_name>
    <description>In the Emergency Department (ED):
After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.
If TCD is normal (FVd&gt;25 cm/sec and PI &lt;1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (&lt; 4-6 hours after TBI), CT scan should not be controlled before patient discharge.
If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).
No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group.</description>
    <arm_group_label>TCD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild TBI (GCS 13-15 on ED admission) with one of the following:

          -  Patient with minor cerebral lesion on initial CT scan (TCDBII i.e. no midline shift,
             visible basal cisterns and haemorrhagic lesion &lt; 25 cc) and GCS 15 after CT scan

          -  OR * Patient with normal initial CT scan (TCDB I) with at least one risk factor :

               -  GCS = 14 after CT scan

               -  and/or alcoholic intoxication

               -  and/or on-going treatment with aspirin

               -  and /or persisting nausea, and/or vomiting and/or headaches

          -  Possibility of home supervision by a third-party

          -  Affiliation to the French social security system

          -  Patient have signed consent form

          -  Possibility to perform a TCD within 8 hours

          -  Stable hemodynamics: systolic blood pressure &gt;90 mmHg, peripheral capillary oxygen
             saturation &gt;92%, hemoglobin &gt; 8 g/dl

        Exclusion Criteria:

          -  CT scan classified as TCDB III - VI

          -  Penetrating head-trauma

          -  Patient under mechanical ventilation

          -  Patients treated with anticoagulants or anti-platelet therapy (except Aspirin)

          -  Hospitalization required by post-traumatic extra-cranial lesion, intoxication (except
             alcoholic), pre-existing condition (including congenital hemostasis disorders) or
             social factors at the discretion of the physician.

          -  Internal Carotid dissection

          -  Post-traumatic lesion in the posterior cerebral fossa

          -  Subject in exclusion period of another interventional study,

          -  Pregnant women, breastfeeding women

          -  Subject under administrative or judicial control, under protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOUZAT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre BOUZAT, MD, PhD</last_name>
    <phone>+33 (0)4 76 76 67 29</phone>
    <email>pbouzat@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anaïs ADOLLE</last_name>
    <phone>+33 (0)4 76 76 67 29</phone>
    <email>arcpar@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Bourg-en-bresse</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrice SERRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe PERRIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maxime MAIGNAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Delphine GARRIGUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karim TAZAROURTE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marion DOUPLAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre MICHELET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Melun</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David SAPIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mustapha SEBBANE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe PES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier BOBBIA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Avicenne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aurélien GUENIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anthony CHAUVIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martha Cancella de Abreu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeremy GUENEZAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bertrand GUIHARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Henri Houzé-Cerfon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Monaco</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yann-Erick CLAESSENS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <reference>
    <citation>Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P, Brazinova A, Büki A, Chesnut RM, Citerio G, Coburn M, Cooper DJ, Crowder AT, Czeiter E, Czosnyka M, Diaz-Arrastia R, Dreier JP, Duhaime AC, Ercole A, van Essen TA, Feigin VL, Gao G, Giacino J, Gonzalez-Lara LE, Gruen RL, Gupta D, Hartings JA, Hill S, Jiang JY, Ketharanathan N, Kompanje EJO, Lanyon L, Laureys S, Lecky F, Levin H, Lingsma HF, Maegele M, Majdan M, Manley G, Marsteller J, Mascia L, McFadyen C, Mondello S, Newcombe V, Palotie A, Parizel PM, Peul W, Piercy J, Polinder S, Puybasset L, Rasmussen TE, Rossaint R, Smielewski P, Söderberg J, Stanworth SJ, Stein MB, von Steinbüchel N, Stewart W, Steyerberg EW, Stocchetti N, Synnot A, Te Ao B, Tenovuo O, Theadom A, Tibboel D, Videtta W, Wang KKW, Williams WH, Wilson L, Yaffe K; InTBIR Participants and Investigators. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017 Dec;16(12):987-1048. doi: 10.1016/S1474-4422(17)30371-X. Epub 2017 Nov 6. Review.</citation>
    <PMID>29122524</PMID>
  </reference>
  <reference>
    <citation>Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien). 2006 Mar;148(3):255-68; discussion 268. Review.</citation>
    <PMID>16311842</PMID>
  </reference>
  <reference>
    <citation>Davis DP, Kene M, Vilke GM, Sise MJ, Kennedy F, Eastman AB, Velky T, Hoyt DB. Head-injured patients who &quot;talk and die&quot;: the San Diego perspective. J Trauma. 2007 Feb;62(2):277-81.</citation>
    <PMID>17297312</PMID>
  </reference>
  <reference>
    <citation>af Geijerstam JL, Britton M. Mild head injury: reliability of early computed tomographic findings in triage for admission. Emerg Med J. 2005 Feb;22(2):103-7. Review.</citation>
    <PMID>15662058</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial Doppler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

